Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679336 | 0.97 | MEN1 (0.35) | MEN1CYP2C9KMT2AALDH1A1CYP3A4 | |
| Ethylene SCHEMBL4673356 | 0.79 | ALDH1A1 (0.32) | ALDH1A1CYP3A4MAPTSIGMAR1MGLL | |
| Ethylene SCHEMBL4679206 | 0.77 | MCHR1 (0.39) | DDB1CRBN | |
| SCHEMBL25635537 | 0.77 | KDM1A (0.44) | MEN1CYP2C9KMT2ACYP3A4 | |
| SCHEMBL14336703 | 0.76 | MEN1 (0.48) | MEN1CYP2C9KMT2AALDH1A1CYP3A4 | |
| Ethylene SCHEMBL4679116 | 0.74 | MEN1 (0.41) | MEN1CYP2C9KMT2AALDH1A1MAPT | |
| SCHEMBL4674917 | 0.74 | HSD11B1 (0.41) | DDB1CRBN | |
| SCHEMBL14102149 | 0.72 | OPRD1 (0.32) | — | |
| Ethylene SCHEMBL4674837 | 0.71 | HPGDS (0.35) | MGLL | |
| SCHEMBL614812 | 0.71 | MEN1 (0.43) | MEN1CYP2C9KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453501-B1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7348328-B2 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1453501-A1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2003047568-A1 | N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | MCHR1, MCHR2, MC4R | MEN1 457/4885CYP2C9 3104/4885KMT2A 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.